OCX חוב להון עצמי oncocyte.com

OncoCyte Corporation (OCX) is currently radically shifting its business model, focusing exclusively on the promotion of profitable molecular tests. Growth is driven by the demand for the DetermaIO system and the expansion of insurance reimbursements for VitaGraft. This chart of the total debt-to-equity metric captured a value of 0.35. Network efficiency is maintained through streamlined express delivery of biosamples to laboratories, which minimizes downtime and strengthens financial stability.

This indicator compares total liabilities to net assets, determining the business's degree of dependence on external borrowing and the financial stability of its capital structure. An analysis of the D/E ratio (total debt to equity) allows for an assessment of bankruptcy risk as OncoCyte Corporation (OCX) deploys costly AI platforms and automated DNA marker analysis systems, which require significant capital expenditures in laboratory infrastructure.